RxDoctor Payments Data

Surender Singh, MD

Cardiovascular Disease · Lancaster, PANPI 1376534339

Payments from drug & device makers

$2,668in general payments, 2019–2025

Across 172 payments — averaging $15.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$706
  • Johnson & Johnson$389
  • Amgen$247
  • Boehringer Ingelheim$212
  • Novo Nordisk$121
  • Pfizer$117
  • plus $876 from 15 others

What the payments were for

  • Food & beverage$2,668100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,668 in reported general payments places this provider in the 55th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$81,965
Medicare patients
522
Services billed
1,342

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban72$92,651
BrilintaTicagrelor16$10,715
Metoprolol Succinate171$2,348
Diltiazem 24hr Er (Cd)Diltiazem Hcl27$1,992
Valsartan36$1,186
Atorvastatin Calcium87$1,125
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide11$1,076
ClopidogrelClopidogrel Bisulfate68$740
Amiodarone Hcl36$711
Rosuvastatin Calcium35$471
Digoxin18$343
Flecainide Acetate12$293
Nitroglycerin25$259
Warfarin Sodium11$254
Losartan Potassium22$213

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$117$92,65172 claims
AstraZenecaBrilinta$59$10,71516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Lancaster

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →